Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

57
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
57
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

5.8K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.8K
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

65
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
65
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

82
Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
82
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

71
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
71
Hazard Ratio01:12

Hazard Ratio

365
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
365

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The CRT-Estimands Framework for Cluster Randomized Trials.

JAMA·2026
Same author

CRT-Estimands Framework: consensus based extension of the ICH E9(R1) addendum for cluster randomised trials.

BMJ (Clinical research ed.)·2026
Same author

STrategies for developing REseArch Methods guidance (STREAM): Protocol.

Journal of clinical epidemiology·2026
Same author

Development of a consensus extension of the estimands framework for cluster randomised trials (CRT-estimands): results from an international Delphi study.

Trials·2025
Same author

Fine-needle aspiration cytology reduces the frequency of surgeries for malignant salivary gland tumors.

Cancer cytopathology·2025
Same author

Stage-dependent effects of systemic ASBT inhibition in a cholestasis-induced cholemic nephropathy mouse model.

JHEP reports : innovation in hepatology·2025

Related Experiment Video

Updated: Nov 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.0K

Testing for similarity of binary efficacy-toxicity responses.

Kathrin Möllenhoff1, Holger Dette2, Frank Bretz3

  • 1Department of Mathematics, Ruhr-Universität Bochum, Universitätsstrasse 150, 44801 Bochum, Germany and Department of Mathematics and Computer Science, Eindhoven University of Technology, Groene Loper 3, 5612 AE Eindhoven, The Netherlands.

Biostatistics (Oxford, England)
|March 19, 2021
PubMed
Summary

This study introduces a new statistical test to assess if two patient groups are similar in binary outcomes like efficacy and toxicity. The method uses curve deviation estimation and bootstrap testing for reliable similarity assessment.

Keywords:
Binary dataBootstrapDose responseGumbel modelLogistic regression

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.1K
High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

8.1K

Related Experiment Videos

Last Updated: Nov 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.0K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.1K
High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

8.1K

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology
  • Statistical Modeling

Background:

  • Clinical trials frequently compare patient groups based on efficacy and toxicity, considering covariates like dose.
  • Assessing group similarity is crucial, especially when outcomes are binary and potentially correlated.

Purpose of the Study:

  • To develop and evaluate a novel statistical test for assessing similarity between two groups with binary outcomes.
  • To extend similarity assessment to correlated binary efficacy and toxicity endpoints.

Main Methods:

  • Development of a test based on estimating maximal deviation between response curves for binary endpoints.
  • Application of a parametric bootstrap test for hypothesis assessment.
  • Utilizing a two-dimensional Gumbel-type model for joint efficacy-toxicity similarity.

Main Results:

  • The proposed methodology effectively assesses similarity for single binary endpoints.
  • The Gumbel-type model provides a framework for evaluating similarity in correlated binary efficacy and toxicity outcomes.
  • Simulation studies and a case study demonstrate the operating characteristics and utility of the methods.

Conclusions:

  • The developed statistical tests offer robust tools for determining group similarity in clinical trials with binary outcomes.
  • The methodology is applicable to both single and multiple correlated binary endpoints, enhancing clinical trial analysis.